港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

534.848

+30.3546.02%

涨家数：31

跌家数：2

平家数：1

市盈率：- -

高：538.151

开：504.695

低：502.716

收：504.495

数据加载中...

化学制药板块盘中走强，海辰药业领涨12.8%

药明巨诺-B盘中异动早盘急速上涨5.49%

A股化学制药板块短线拉升，易明医药、昂利康封板涨停，海辰药业涨超10%，海森药业、尔康制药、德展健康、福安药业、向日葵等

歌礼制药-B盘中异动早盘股价大涨5.23%报8.050港元

中国抗体-B盘中异动大幅拉升5.63%报2.250港元

智通决策参考︱医药作为主线还会反复炒作

【中信建投：持续看好创新药产业技术驱动周期】中信建投指出，美国临床肿瘤学会年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。近年来随着国内企业创新管线持续推进，国内创新药数据登上ASCO的比例和口头汇报比例持续提高。2025年共有73项研究中选口头报告，其中11个LBA。中国药企持续发力，创新度持续提升，我们持续看好创新药产业技术驱动周期，建议持续关注双抗及多抗、ADC及小分子疗法等领域相关企业。

银河证券：看好创新药产业链在今年持续良好表现

银河证券：医药行情将迎来持续性修复看好创新药产业链在今年持续良好表现

国海金贝壳

歌礼制药-B(01672)将在ADA第85届科学会议上以壁报形式报告口服小分子GLP-1R激动剂ASC30及脂肪靶向、减重不减肌候选药物ASC47的研究结果

绿谷医药阿尔茨海默症药物停产；全球首个PROTAC药物申报上市 | 医药早参

每日经济新闻

华泰证券：关注科技中拥挤度相对低位的AI算力芯片等

康宁杰瑞制药-B：控股股东完成配售现有股份

“吃药行情”站在十字路口！基金把脉三大技术脉络

ASCO2025重点公司简评(三)：亚盛医药

浦银国际证券有...

医药生物行业跟踪周报：中国创新药在ASCO表现超预期，关注信达生物、科伦博泰等

港股次新股狂欢：17只翻倍牛股涌现，新消费、创新药领跑，中报临近警惕

新消费行情还能持续多久？创新药是今年的重要主线

每日经济新闻

中国抗体(03681.HK)中国区总裁离任

阿斯达克财经

同源康医药-B申请H股全流通

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":534.8484,"timestamp":1749456491274,"preClose":504.49472,"halted":0,"volume":272764563,"delay":0,"changeRate":0.060166,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":30.353668,"latestTime":"06-09 16:00:00","open":504.69467,"high":538.15076,"low":502.7157,"amount":4827861032,"amplitude":0.070239,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1749519000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749432600000,1749441600000],[1749445200000,1749456000000]],"pbRate":4.156734,"peRate":-25.602863,"turnoverRate":0.010276,"increases":31,"decrements":2,"flats":0,"marketCap":311187749504,"floatMarketCap":286340775408},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":538.15076,"amplitude":0.070239,"preClose":504.49472,"low":502.7157,"pbRate":"4.156734","latestPrice":534.8484,"volume":272764563,"delay":0,"open":504.69467,"prevYearClose":331.1933,"prevWeekClose":504.495,"prevMonthClose":491.683,"prevQuarterClose":455.082,"fiveDayClose":474.737,"twentyDayClose":437.583,"sixtyDayClose":419.757,"secType":"PLATE","market":"HK","turnoverRate":0.010276,"peRate":-25.602863,"marketCap":311187749504,"floatMarketCap":286340775408,"timestamp":1749456491274,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":31,"down":2,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542878036","title":"化学制药板块盘中走强，海辰药业领涨12.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542878036","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542878036?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:36","pubTimestamp":1749432990,"startTime":"0","endTime":"0","summary":"6月9日，化学制药板块盘中上涨1.51%，海辰药业领涨12.8%，昂利康涨超9%，常山药业涨超7%，永安药业、悦康药业涨超6%。板块实时资金流向显示，今日超大单净流出5806.76万元，今日小单净流出3443.15万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/09093650939029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","01477","BK1191","BK0239","300584"],"gpt_icon":0},{"id":"2542878108","title":"药明巨诺-B盘中异动 早盘急速上涨5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542878108","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542878108?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:35","pubTimestamp":1749432945,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时35分，药明巨诺-B股票出现异动，股价快速上涨5.49%。截至发稿，该股报1.920港元/股，成交量3.45万股，换手率0.01%，振幅4.95%。药明巨诺-B股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，中国抗体-B、金斯瑞生物科技、药明巨诺-B涨幅较大，振幅较大的相关个股有中国抗体-B、基石药业-B、荃信生物-B，振幅分别为15.96%、6.39%、6.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093546a6ffbdf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093546a6ffbdf5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02126","BK1161","BK1574"],"gpt_icon":0},{"id":"2542878696","title":"A股化学制药板块短线拉升，易明医药、昂利康封板涨停，海辰药业涨超10%，海森药业、尔康制药、德展健康、福安药业、向日葵等","url":"https://stock-news.laohu8.com/highlight/detail?id=2542878696","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542878696?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:33","pubTimestamp":1749432782,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["399300","000813","01477","BK1574","300267","BK0056","BK0132","BK0028","300584","002940","159982","300111","BK0077","BK0114","BK0239","BK1191","002826","001367","BK0054","BK0060","BK0156","300194","BK0033"],"gpt_icon":0},{"id":"2542873194","title":"歌礼制药-B盘中异动 早盘股价大涨5.23%报8.050港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542873194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542873194?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:31","pubTimestamp":1749432666,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时31分，歌礼制药-B股票出现波动，股价快速拉升5.23%。截至发稿，该股报8.050港元/股，成交量21.8万股，换手率0.02%，振幅3.01%。资金方面，该股资金流入101.742万港元，流出5.607万港元。歌礼制药-B股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，中国抗体-B、歌礼制药-B、来凯医药-B涨幅较大，振幅较大的相关个股有中国抗体-B、来凯医药-B、科济药业-B，振幅分别为6.57%、4.42%、3.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093106a49f837c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609093106a49f837c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","BK1515","BK1191","BK1161","01477","BK1574"],"gpt_icon":0},{"id":"2542987845","title":"中国抗体-B盘中异动 大幅拉升5.63%报2.250港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542987845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542987845?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 09:30","pubTimestamp":1749432634,"startTime":"0","endTime":"0","summary":"2025年06月09日早盘09时30分，中国抗体-B股票出现异动，股价快速拉升5.63%。截至发稿，该股报2.250港元/股，成交量33.93万股，换手率0.03%，振幅6.10%。资金方面，该股资金流入35.0613万港元，流出18.5064万港元。中国抗体-B股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，中国抗体-B、歌礼制药-B、加科思-B涨幅较大，振幅较大的相关个股有中国抗体-B、来凯医药-B、科济药业-B，振幅分别为6.10%、4.42%、3.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506090930359513fc6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506090930359513fc6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"2542827742","title":"智通决策参考︱医药作为主线还会反复炒作","url":"https://stock-news.laohu8.com/highlight/detail?id=2542827742","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542827742?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:40","pubTimestamp":1749429627,"startTime":"0","endTime":"0","summary":"本周一，国家统计局将公布5月CPI、PPI数据。在市场没有明确热点之下，医药作为主线还会反复炒作。其它方向，根据知情人士透露，美国商务部已向包括西屋电气和艾默等美国核设备供应商发出通知，暂停对中国的核电设备出口许可。电力设备方向自主可控将继续炒作。特朗普减税法案在众议院通过、中美首脑对话重启贸易谈判。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1302691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0456827905.SGD","BK1594","LU0828238088.HKD","BK1509","03606","IE0034224299.USD","BK1516","LU0455707207.USD","LU0572944931.SGD","BK1515","BK1583","LU0051755006.USD","BK1574","LU0502904849.HKD","LU1655091616.SGD","LU0269904917.USD","09939","01896","LU0327786744.USD","BK1161","BK1142","LU2242644610.SGD","159938","BK1591","BK1581","BK1144","LU0509642566.USD","BK1128","BK1554"],"gpt_icon":0},{"id":"2542959827","title":"【中信建投：持续看好创新药产业技术驱动周期】中信建投指出，美国临床肿瘤学会年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。近年来随着国内企业创新管线持续推进，国内创新药数据登上ASCO的比例和口头汇报比例持续提高。2025年共有73项研究中选口头报告，其中11个LBA。中国药企持续发力，创新度持续提升，我们持续看好创新药产业技术驱动周期，建议持续关注双抗及多抗、ADC及小分子疗法等领域相关企业。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542959827","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542959827?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:27","pubTimestamp":1749428850,"startTime":"0","endTime":"0","summary":"中信建投指出，美国临床肿瘤学会年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。近年来随着国内企业创新管线持续推进，国内创新药数据登上ASCO的比例和口头汇报比例持续提高。2025年共有73项研究中选口头报告，其中11个LBA。中国药企持续发力，创新度持续提升，我们持续看好创新药产业技术驱动周期，建议持续关注双抗及多抗、ADC及小分子疗法等领域相关企业。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/09082750937377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4231","06978","BK1161","BK1574","601066","159992","BK0276","BK4080","ADC"],"gpt_icon":0},{"id":"2542275598","title":"银河证券：看好创新药产业链在今年持续良好表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2542275598","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542275598?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:23","pubTimestamp":1749428638,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","09939","159938","BK1574","399265","BK1515","159992","06978"],"gpt_icon":0},{"id":"2542282798","title":"银河证券：医药行情将迎来持续性修复 看好创新药产业链在今年持续良好表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2542282798","media":"国海金贝壳","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542282798?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:15","pubTimestamp":1749428100,"startTime":"0","endTime":"0","summary":"来源：国海金贝壳中国银河证券研报表示，医药板块经历较长时间调整，整体估值处于较低水平，且公募持仓低配，2025年在支持引导商保发展的政策背景下，支付端有望边际改善， 创新药 械有望获益。医药行情将迎来持续性修复，结构性机会依然存在，从短期和中长期确定性增长角度来选择标的，看好创新药产业链在今年持续良好表现。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-06-09/doc-inezmrrq4677599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","06978","09939","BK1161","BK1515","BK1574","159992"],"gpt_icon":0},{"id":"2542827886","title":"歌礼制药-B(01672)将在ADA第85届科学会议上以壁报形式报告口服小分子GLP-1R激动剂ASC30及脂肪靶向、减重不减肌候选药物ASC47的研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2542827886","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542827886?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 08:09","pubTimestamp":1749427785,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，公司董事会宣布将在美国芝加哥举行的美国糖尿病协会第85届科学会议上以壁报形式报告口服小分子GLP-1受体激动剂 ASC30以及脂肪靶向、减重不减肌候选药物ASC47的早期研究数据。ADA已成为全球糖尿病领域最具影响力的非营利组织之一。其年度科学会议被视为行业风向标，展示前沿临床实践与研究方向。ADA第85届科学会议将于今年6月20至23日在美国芝加哥举行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1302675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","GLP","BK1515","BK4590","BK1191","01672","01477","BK1161","BK4144"],"gpt_icon":0},{"id":"2542822447","title":"绿谷医药阿尔茨海默症药物停产；全球首个PROTAC药物申报上市 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2542822447","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542822447?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 07:56","pubTimestamp":1749426977,"startTime":"0","endTime":"0","summary":"丨2025年6月9日星期一丨NO.1辉瑞/Arvinas明星PROTAC药物申报上市当地时间6月6日，Arvinas宣布，已与合作伙伴辉瑞一起向FDA（美国食品药品监督管理局）递交了Vepdegestrant的上市申请（NDA），用于治疗既往接受过内分泌药物治疗的、携带ESR1突变的ER+/HER2-晚期或转移性乳腺癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506093424868491.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506093424868491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09939","BK1161","BK1515"],"gpt_icon":0},{"id":"2542482248","title":"华泰证券：关注科技中拥挤度相对低位的AI算力芯片等","url":"https://stock-news.laohu8.com/highlight/detail?id=2542482248","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542482248?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 07:55","pubTimestamp":1749426959,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1564","LU1781817850.SGD","US2Y.BOND","000016.SH","BK0011","US3Y.BOND","US5Y.BOND","BK1574","FXP","LU1580142542.USD","BK0183","US6M.BOND","06886","601688","BK0028","BK0184","FOMC","510030","LU1328615791.USD","US10Y.BOND","BK0196","XPP","600663","LU1064130708.USD","LU1064131003.USD","000300.SH","159940","US12M.BOND","US7Y.BOND","159992","BK0188","159601","CNmain","BK0187","512550","LU1979443071.USD","BK0276","HTSC.UK","LU1934453819.USD","BK0020","06978","159813","BK0053","BK0273","BK4077","BK1161","US30Y.BOND","LU2148510915.USD","510050","YXI"],"gpt_icon":0},{"id":"2542224468","title":"康宁杰瑞制药-B：控股股东完成配售现有股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2542224468","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542224468?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 07:47","pubTimestamp":1749426420,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　康宁杰瑞制药-B（09966）公布，配售事项已于2025年6月5日完成。合共1460万股股份（于本公告日期占公司已发行股本（包括库存股份）约1.51%）已由独家配售代理以每股股份8.05港元的价格成功配售。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-06-09/doc-inezmrrs1443027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2542882284","title":"“吃药行情”站在十字路口！基金把脉三大技术脉络","url":"https://stock-news.laohu8.com/highlight/detail?id=2542882284","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542882284?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 07:23","pubTimestamp":1749424980,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　一面是“电子群开始研究创新药”，一面是知名基金经理喊出“创新药的泡沫远比上轮CXO大”，高歌猛进的“吃药行情”站在了分歧的十字路口。　　面对火热行情，分歧的声音时而出现。技术脉络和投资主线如何把握？中国创新药在全球产业链中的地位究竟如何？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-06-09/doc-inezmmis4794056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2542871918","title":"ASCO2025重点公司简评(三)：亚盛医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2542871918","media":"浦银国际证券有...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542871918?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 00:00","pubTimestamp":1749398400,"startTime":"0","endTime":"0","summary":"亚盛于2025 ASCO 大会以口头报告形式展示了Lisaftoclax 联用在美国和澳洲人群包含AML MDS 在内的恶性髓系肿瘤数据，其中Venetoclax耐药R/R AML/MPAL 人群显示出的31.8% ORR 令人惊喜。管理层表示，目前计划将Ventoclax 耐药群体进一步扩大临床样本量至40-50 例患者，若数据积极，后续或有望展开美国R/R AML关键性试验。绝大多数不良事件可控制、可恢复、可耐受。管理层表示，若后续中国数据能够重复先前美国研究的积极疗效，公司将与监管部门进一步探讨后续注册临床研究可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060911541497773d40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060911541497773d40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","AAPG","BK1574","06855"],"gpt_icon":0},{"id":"2541522825","title":"医药生物行业跟踪周报：中国创新药在ASCO表现超预期，关注信达生物、科伦博泰等","url":"https://stock-news.laohu8.com/highlight/detail?id=2541522825","media":"东吴证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541522825?lang=zh_cn&edition=fundamental","pubTime":"2025-06-08 22:07","pubTimestamp":1749391630,"startTime":"0","endTime":"0","summary":"中国创新药闪耀ASCO会议，突破多个实体瘤治疗瓶颈。2025ASCO会议共有来自中国的73项口头报告，数量创下历史新高。中国企业发布双抗研究约34项，占整体双抗研究的比例约49%。该药为全球首款完成患者给药的环形RNA类药物，曾于1月获中国NMPA IND批准。具体标的选择思路：从成长性角度选股，主要集中创新药领域，关注信达生物、泽璟制药、百济神州、科伦博泰、恒瑞医药、三生制药、百利天恒、联邦制药、康方生物、迪哲医药、海思科等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060822071597767da0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025060822071597767da0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","BK1583","BK1589","LU2328871848.SGD","01801","LU2488822045.USD","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"2541691828","title":"港股次新股狂欢：17只翻倍牛股涌现，新消费、创新药领跑，中报临近警惕","url":"https://stock-news.laohu8.com/highlight/detail?id=2541691828","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541691828?lang=zh_cn&edition=fundamental","pubTime":"2025-06-08 19:15","pubTimestamp":1749381318,"startTime":"0","endTime":"0","summary":"港股自去年9月以来流动性和估值持续改善，伴随着主要指数震荡上行，创新药、新消费走出结构性牛市行情，其中的次新股正在成为资金获取超额收益的主要战场。次新股是指上市公司发行的股票上市时间较短，通常被界定为上市2年内。截至6月6日，有17只港股次新股年内股价翻倍（2023年6月以后上市的港股，下同）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506083424798141.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506083424798141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978","HSTECH","YANG","BK4614"],"gpt_icon":1},{"id":"2541409558","title":"新消费行情还能持续多久？创新药是今年的重要主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2541409558","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541409558?lang=zh_cn&edition=fundamental","pubTime":"2025-06-08 17:48","pubTimestamp":1749376127,"startTime":"0","endTime":"0","summary":"6月首周沪指迎来4连阳，A股主要股指均实现小幅震荡上扬，创业板指数领涨，周涨幅达到2.32%。交投方面，本周A股日均成交额为12089亿元，较上周上升1149.50亿元；日均换手率为1.3945%,较上周上升0.10个百分点，总体来看，投资者情绪有所回暖。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506083424793165.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506083424793165.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2541840344","title":"中国抗体(03681.HK)中国区总裁离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2541840344","media":"阿斯达克财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541840344?lang=zh_cn&edition=fundamental","pubTime":"2025-06-08 17:30","pubTimestamp":1749375000,"startTime":"0","endTime":"0","summary":"中国抗体－Ｂ(03681.HK) 公布，王善春先生不再担任集团总裁(中国区)，即日生效。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201124105435391_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201124105435391_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1445268/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03681","BK1161","BK1574"],"gpt_icon":0},{"id":"2541572847","title":"同源康医药-B申请H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2541572847","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541572847?lang=zh_cn&edition=fundamental","pubTime":"2025-06-08 16:11","pubTimestamp":1749370260,"startTime":"0","endTime":"0","summary":"同源康医药-B（02410）发布公告，公司已于2025年6月6日向中国证券监督管理委员会提交申请，计划将461万股非上市股份转换为H股并在香港联合交易所上市。此次申请是依据相关法律法规及监管指引进行的，标志着公司向H股全流通迈出了重要一步。根据公告，转化的非上市股份占公司已发行股本总额3.71亿股的1.24%。在获得所有相关监管机构的批准后，这些股份将能够在联交所主板上市交易。公司将持续关注申请进展，并在适当时机发布进一步公告，提醒股东及潜在投资者保持审慎。（文章来源：财中社）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250608161948a6ff0489&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250608161948a6ff0489&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1574","02410","BK1161","BK1515"],"gpt_icon":0}],"pageSize":20,"totalPage":32,"pageCount":3,"totalSize":623,"code":"91000000","status":"200"}]}}